INTRODUCTION: One of the most common complaints in patients with end-stage renal disease (ESRD) is uremic pruritus. In the recent years, many drugs have been proposed for its treatment which have had paradoxical outcomes. We studied the antipruritus effect of montelukast sodium, a leukotriene receptor antagonist, in patients on hemodialysis. MATERIALS AND METHODS: The study was conducted as randomized, single-blind, placebo-controlled crossover study in 5 hemodialysis centers. Sixteen patients with refractory pruritus were selected and were divided into 2 groups to receive firstly montelukast and then placebo, or vice versa. Patients were treated by montelukast tablets, 10 mg daily, for 20 days and the washout period was 14 days. RESULTS: Of 16 patients whom were included in the study, 1 died during the placebo period of myocardial infarction and another patient who receivedmontelukast for 20 days faced hemoglobin decrease during the placeboperiod diagnosed as myelodysplastic syndrome. At the end of the treatment with montelukast, pruritus was reduced by 35% (95% CI, 9.5% to 62.5%), while it was reduced 7% (95% CI, 0.5% to 15.9%) with placebo (P = .002). The patients' compliance was assessed satisfactory, except for 1 patient who exited the study due to anemia. CONCLUSIONS:Montelukast is more effective than placebo in the treatment of uremic pruritus not responding to the currently available antipruritus drugs, and it can be considered as a new and rather safe and effective treatment option in uremic patients.
RCT Entities:
INTRODUCTION: One of the most common complaints in patients with end-stage renal disease (ESRD) is uremic pruritus. In the recent years, many drugs have been proposed for its treatment which have had paradoxical outcomes. We studied the antipruritus effect of montelukast sodium, a leukotriene receptor antagonist, in patients on hemodialysis. MATERIALS AND METHODS: The study was conducted as randomized, single-blind, placebo-controlled crossover study in 5 hemodialysis centers. Sixteen patients with refractory pruritus were selected and were divided into 2 groups to receive firstly montelukast and then placebo, or vice versa. Patients were treated by montelukast tablets, 10 mg daily, for 20 days and the washout period was 14 days. RESULTS: Of 16 patients whom were included in the study, 1 died during the placebo period of myocardial infarction and another patient who received montelukast for 20 days faced hemoglobin decrease during the placebo period diagnosed as myelodysplastic syndrome. At the end of the treatment with montelukast, pruritus was reduced by 35% (95% CI, 9.5% to 62.5%), while it was reduced 7% (95% CI, 0.5% to 15.9%) with placebo (P = .002). The patients' compliance was assessed satisfactory, except for 1 patient who exited the study due to anemia. CONCLUSIONS:Montelukast is more effective than placebo in the treatment of uremic pruritus not responding to the currently available antipruritus drugs, and it can be considered as a new and rather safe and effective treatment option in uremic patients.
Authors: Hugh C Rayner; Maria Larkina; Mia Wang; Matthew Graham-Brown; Sabine N van der Veer; Tevfik Ecder; Takeshi Hasegawa; Werner Kleophas; Brian A Bieber; Francesca Tentori; Bruce M Robinson; Ronald L Pisoni Journal: Clin J Am Soc Nephrol Date: 2017-09-18 Impact factor: 8.237